**Response document for MHRA public consultation on the proposal to make Lovima available from pharmacies**

**Ref: ARM 99**

**MHRA proposes to permit supply of Lovima in pharmacies because we consider that the evidence presented in this application demonstrates that the product does not meet the POM criteria set out in legislation.  Your response should address why you agree or disagree with this conclusion and any additional safeguards you consider to be necessary in pharmacies.  We will review all responses received to see if the evidence presented changes our conclusion about the product not meeting the POM criteria.**

**Your details**

**Name:**

**Position (if applicable):**

**Organisation (if applicable):**

**Email:**

|  |
| --- |
| * 1. **Do you consider that Lovima should be available as a Pharmacy (P) medicine?**

Yes 🞏 No 🞏 Not sure 🞏Please provide any comments or evidence to support your response: |

|  |
| --- |
| * 1. **Do you have any specific comments on the leaflet, label or pharmacy consultation checklist provided at Annexes 2, 3 & 5?**
 |

|  |
| --- |
| * 1. **Do you have any other comments on the reclassification?**
 |

|  |
| --- |
| * 1. **The MHRA may publish consultation responses. Do you want your response to remain confidential?**

Yes 🞏 Partially\* 🞏 No 🞏 \*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete. |

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gov.uk) to arrive by **Friday 5 March 2021.** Contributions received after that date cannot be included in the exercise.